索拉非尼治疗晚期肾癌的近期及远期疗效分析  

Analysis of Recent and Long-term Efficacy of Sorafenib in the Treatment of Advanced Renal Cell Carcinoma

作　　者：丁素银[1] 

机构地区：[1]河北保定恒兴中西医结合医院肿瘤内科,保定071051

出　　处：《中国医药导刊》2015年第10期1030-1032,共3页Chinese Journal of Medicinal Guide

摘　　要：目的：探讨索拉非尼治疗晚期肾癌的近期及远期疗效。方法：对2011年8月-2013年8月我院收治的76例晚期肾癌患者的临床资料进行统计分析。结果：观察组患者治疗的总有效率78.95%（30/38）明显比对照组57.89%（22/38）高（P〈0.05）,手足皮肤反应、皮疹/溃疡发生率18.42%（7/38）、10.53%（4/38）均明显比对照组（0、0）高（P〈0.05）,发热、恶心发生率7.89%（3/38）、2.63%（1/38）均明显比对照组26.32%（10/38）、15.79%（6/38）低（P〈0.05）,PF、RF、EF评分均明显比对照组高（P〈0.05）,1、3、5年生存率68.4%（26/38）、31.6%（12/38）、21.1%（8/38）均明显比对照组52.6%（20/38）、15.8%（6/38）、5.3%（2/38）高（P〈0.05）。结论：索拉非尼治疗晚期肾癌的近期及远期疗效均较显著。Objective： To investigate the recent and long-term efficacy of sorafenib in the treatment of advanced renal cell carcinoma.Methods：The clinical data of 76 cases of patients with advanced kidney cancer in our hospital from August 2011 to August 2013 were statistically analyzed.Results：The total effective treatment of patients in the observation group 78.95%（30/38） was significantly higher than the control group 57.89%（22/38）（P〈0.05）, the hand-foot skin reaction, rash / ulcer incidence 18.42%（7/38）, 10.53%（4/38） were significantly higher than the control group（0,0）（P〈0.05）, the fever, nausea incidence 7.89%（3/38）, 2.63%（1/38） were significantly lower than the control group 26.32%（10/38）,15.79%（6/38）（P〈0.05）,the PF,RF,EF scores were significantly higher than the control group（P〈0.05）,the 1,3,5-year survival rate were 68.4%（26/38）,31.6%（12/38）,21.1%（8/38） were significantly higher than the control group 52.6%（20/38）,15.8%（6/38）,5.3%（2/38）（P〈0.05）.Conclusion：The recent and long-term efficacy of sorafenib is significant in the treatment of advanced renal cell carcinoma,so it is worthy of promoting.

关 键 词：索拉非尼 晚期肾癌 近期及远期疗效 

分 类 号：R737.11[医药卫生—肿瘤]